share_log

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54

HC Wainwright & Co.維持對UroGen Pharma的買入,將目標股價提高至54美元
Benzinga ·  2023/08/01 06:21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $23 to $54.

HC Wainwright & Co. 分析師Raghuram Selvaraju維持UroGen Pharma(納斯達克股票代碼:URGN)的買入,並將目標股價從23美元上調至54美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論